logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Seasonal Allergic Rhinitis

    FiltersReset Filters
    19 results

    • azelastine

      (Azelastine)
      Ascend Laboratories, LLC
      Usage: Azelastine HCl Nasal Spray is indicated for treating symptoms of seasonal allergic rhinitis in adults and children 5 years and older, as well as vasomotor rhinitis symptoms in adults and adolescents aged 12 years and older.

    • azelastine hydrochloride

      (AZELASTINE HYDROCHLORIDE)
      Aurobindo Pharma Limited
      Usage: Azelastine hydrochloride Nasal Spray is indicated for treating seasonal allergic rhinitis in adults and children aged 5 and older, as well as vasomotor rhinitis in adults and adolescents aged 12 and older.

    • celestone soluspan

      (Betamethasone Acetate and Betamethasone Sodium Phosphate)
      Organon LLC
      Usage: CELESTONE SOLUSPAN Injectable Suspension is indicated for treating severe allergic conditions, dermatologic diseases, endocrine disorders, gastrointestinal diseases, and various hematologic disorders. It is also used for certain neoplastic diseases, nervous system issues, ophthalmic diseases, renal diseases, respiratory diseases, rheumatic disorders, and specific dermatological conditions via different administration routes.

    • dexamethasone

      (dexamethasone)
      Amneal Pharmaceuticals NY LLC
      Usage: This drug is indicated for severe allergic conditions, dermatologic and endocrine disorders, gastrointestinal issues, hematologic disorders, certain cancers, acute nervous system conditions, ocular inflammation, renal diseases, respiratory conditions, and as adjunctive therapy for rheumatic disorders. It addresses various severe and chronic health issues unresponsive to standard treatments.

    • ipratropium bromide

      (IPRATROPIUM BROMIDE)
      Advagen Pharma Ltd
      Usage: Ipratropium Bromide Nasal Solution, 0.06% is used for symptomatic relief of rhinorrhea in adults and children (5 years and older) with the common cold or seasonal allergic rhinitis. It does not relieve nasal congestion or sneezing and is not established for use beyond specified time frames.

    • methylprednisolone acetate

      (METHYLPREDNISOLONE ACETATE)
      Sandoz Inc.
      Usage: Methylprednisolone acetate is indicated for use in allergic conditions, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, and various other conditions. It can be administered intramuscularly, intra-articularly, or intralesionally for acute episodes in disorders like arthritis, dermatological lesions, and certain cancers.

    • methylprednisolone acetate

      (Methylprednisolone acetate)
      Amneal Pharmaceuticals NY LLC
      Usage: Methylprednisolone acetate injectable suspension is indicated for intramuscular, intra-articular, and intralesional administration to treat severe allergic conditions, dermatologic and endocrine disorders, gastrointestinal diseases, hematologic disorders, rheumatic conditions, neoplastic diseases, and specific ophthalmic and respiratory diseases, among others.

    • methylprednisolone sodium succinate

      (METHYLPREDNISOLONE SODIUM SUCCINATE)
      Fresenius Kabi USA, LLC
      Usage: Methylprednisolone Sodium Succinate is indicated for intravenous or intramuscular use in severe allergic reactions, dermatologic and endocrine disorders, gastrointestinal diseases, hematologic conditions, neurological conditions, ophthalmic diseases, renal issues, respiratory diseases, and as adjunct therapy in rheumatic disorders and certain neoplastic diseases when oral therapy is not feasible.

    • methylprednisolone sodium succinate

      (Methylprednisolone Sodium Succinate)
      Hikma Pharmaceuticals USA Inc.
      Usage: Methylprednisolone Sodium Succinate for Injection is indicated for severe allergic conditions, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, certain neoplastic diseases, acute multiple sclerosis exacerbations, various ophthalmic and renal diseases, respiratory issues, and rheumatic disorders when oral therapy is not feasible.

    • montelukast

      (Montelukast)
      XLCare Pharmaceuticals Inc.
      Usage: Montelukast sodium tablets are indicated for the prophylaxis and chronic treatment of asthma, prevention of exercise-induced bronchoconstriction (EIB), and relief of symptoms of seasonal and perennial allergic rhinitis in patients aged 15 years and older. Caution is advised due to potential neuropsychiatric risks.